207 related articles for article (PubMed ID: 32458030)
1. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
[TBL] [Abstract][Full Text] [Related]
2. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
[TBL] [Abstract][Full Text] [Related]
3. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
4. A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
Shibata Y; Matsumoto N; Murase R; Kubota Y; Ishida H; Shimada K; Fujita KI
Cancer Chemother Pharmacol; 2023 Dec; 92(6):465-474. PubMed ID: 37653272
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5'-Deoxy-5-fluorocytidine, and Creatinine Clearance.
Inaishi T; Fujita KI; Matsumoto N; Shimokata T; Maeda O; Kikumori T; Hattori N; Nakayama G; Ando Y
In Vivo; 2020; 34(6):3539-3544. PubMed ID: 33144465
[TBL] [Abstract][Full Text] [Related]
6. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
7. Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.
Liu D; Li X; Li X; Wang H; Dong M
Cancer Chemother Pharmacol; 2021 May; 87(5):681-687. PubMed ID: 33586000
[TBL] [Abstract][Full Text] [Related]
8. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
9. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations.
Sáez-Belló M; Mangas-Sanjuán V; Martínez-Gómez MA; López-Montenegro Soria MÁ; Climente-Martí M; Merino-Sanjuán M
Br J Clin Pharmacol; 2021 Mar; 87(3):905-915. PubMed ID: 32559325
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr D; Gray V; West H; Houlston RS; Escott-Price V; Cheadle JP
Int J Cancer; 2021 Nov; 149(9):1713-1722. PubMed ID: 34270794
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
15. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
[TBL] [Abstract][Full Text] [Related]
16. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
18. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Fornaro L; Masi G; Bursi S; Loupakis F; Vasile E; Antonuzzo A; Chiara S; Pfanner E; Di Paolo A; Bocci G; Del Tacca M; Falcone A
Cancer Chemother Pharmacol; 2009 Apr; 63(5):965-9. PubMed ID: 18839174
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
[TBL] [Abstract][Full Text] [Related]
20. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
